Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Synaptogenix Inc | SNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.57 | 04:17:36 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.57 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.5275 - 47.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.57 | USD |
Synaptogenix Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 93.19M | 20.39M | - | 0 | -13.78M | -0.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Synaptogenix News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNPX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.69 | 4.9586 | 4.2001 | 4.62 | 57,591 | -0.12 | -2.56% |
| 1 Month | 4.96 | 6.217 | 3.865 | 4.63 | 249,773 | -0.39 | -7.86% |
| 3 Months | 4.74 | 7.2225 | 3.5275 | 5.10 | 742,977 | -0.17 | -3.59% |
| 6 Months | 7.3775 | 8.775 | 3.5275 | 5.57 | 566,019 | -2.81 | -38.05% |
| 1 Year | 23.50 | 47.00 | 3.5275 | 11.94 | 663,420 | -18.93 | -80.55% |
| 3 Years | 187.50 | 362.50 | 3.5275 | 78.95 | 351,595 | -182.93 | -97.56% |
| 5 Years | 187.50 | 362.50 | 3.5275 | 78.95 | 351,595 | -182.93 | -97.56% |
Synaptogenix Description
| Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. |
